Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910269 · ClinicalTrials.gov registry record · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
A Phase 3 study of Covid19 and COVID, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
- 20
- Study locations
NCT04910269 is a Phase 3 study of Covid19 and COVID that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 820 participants, below the 2,694-participant average among 94 other Covid19 trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04910269, a Phase 3 study of Covid19 and COVID, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that assesses the participant's clinical status seven days after the infusion of hIVIG or placebo. 1. Asymptomatic and no limitations in usual activity due to COVID-19 2. Mild COVID-19 illness or minor limitations to usual activity 3. Moderate COVID-19 illness and with major limitations to usual activity 4. Severe COVID-19 or serious disease manifestation from COVID-19 5. Critical illness from COVID-19 or Death Two strata of participants will be identified for analysis purposes. Stratum 2 will be participants who receive direct-acting antivirals (DAAs) or other anti-SARS-CoV2 agents that are approved/available and recommended for use as part of standard of care (SOC), estimated to be about 20% of participants. Stratum 1 will be participants who do not receive this agents, estimated to be about 80% of participants.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Study Locations (20)
California
- VA Northern California Health Care System (074-023) - Mather
- Stanford University Hospital & Clinics (Site 203-003) - Palo Alto
- San Francisco VAMC (Site 074-002) - San Francisco
Texas
- Hendrick Medical Center - Abilene
- CHRISTUS Spohn Shoreline Hospital - Corpus Christi
- UT Southwestern Medical Center - Dallas
District of Columbia
- MedStar Health Research Institute - Washington D.C.
- Washington DC Veterans Affairs Medical Center - Washington D.C.
Michigan
- Henry Ford Health System Site (014-001) - Detroit
- Infusion Associates - Grand Rapids
New York
- Mount Sinai Beth Israel Hospital - New York
- Icahn School of Medicine at Mount Sinai - New York
Virginia
- UVA Health System, University Hospital (Site 210-003) - Charlottesville
- Carilion Medical Center (Site 080-018) - Roanoke
Arizona
- Southern Arizona VA Healthcare System (074-009) - Tucson
Colorado
- Rocky Mountain Regional VA Medical Center (074-010) - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04910269
The ClinicalTrials.gov registry entry for NCT04910269 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,694-participant average among 94 other Covid19 trials with a reported enrollment target (70% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04910269 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04910269 about?
NCT04910269 is a clinical study titled "Outpatient Treatment With Anti-Coronavirus Immunoglobulin". The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acut...
What is the current status of trial NCT04910269?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2021-08-06. Estimated completion is 2026-08-01.
What conditions does trial NCT04910269 study?
This clinical trial studies the following conditions: Covid19, COVID, SARS-CoV2 Infection.
What interventions are being tested in trial NCT04910269?
The interventions under investigation include: Placebo (OTHER), Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04910269?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04910269 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Aggrenox To Treat Acute Covid-19
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Contrast Enhanced Ultrasound in COVID-19
COMPLETED · Phase 3
-
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.